- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 19.09. | ASCENTAGE-B (06855): INTERIM REPORT 2025 | - | HKEx | ||
| 16.09. | ASCENTAGE PHARMA GROUP INTERNATIONAL - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 28.08. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| ASCENTAGE PHARMA GROUP INTERNATIONAL ADR Aktie jetzt für 0€ handeln | |||||
| 21.08. | Ascentage Pharma Group International GAAP EPS of -$0.24, revenue of $32.6M | 1 | Seeking Alpha | ||
| 21.08. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates | 196 | GlobeNewswire (Europe) | Product sales from Olverembatinib in the first half of 2025 increased 93% year-over-year to US$30.3 million (RMB217.4 million), primarily attributable to the expansion of NRDL coverageCommenced commercial... ► Artikel lesen | |
| 21.08. | ASCENTAGE-B (06855): ANNOUNCEMENT OF UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2025 | 2 | HKEx | ||
| 18.08. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 18.08. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA | 135 | GlobeNewswire (Europe) | ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery... ► Artikel lesen | |
| 18.08. | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - GLOBAL REGISTRATIONAL PHASE III STUDY OF LISAFTOCLAX FOR FIRST-LINE TREATMENT OF HR-MDS CLEARED BY FDA AND ... | 1 | HKEx | ||
| 08.08. | ASCENTAGE-B (06855): NOTICE OF BOARD MEETING | 2 | HKEx | ||
| 07.08. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 07.08. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025 | 1 | GlobeNewswire (USA) | ||
| 01.08. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma to Participate in Evercore China Biotech Summit | 1 | GlobeNewswire (USA) | ||
| 25.07. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 25.07. | ASCENTAGE-B (06855): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 25.07. | ASCENTAGE-B (06855): CLOSING OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE | 2 | HKEx | ||
| 17.07. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.07. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement | 1 | GlobeNewswire (USA) | ||
| 15.07. | ASCENTAGE-B (06855): PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx |
1 2 3 4 Weiter >>
65 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,470 | -1,56 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
| EVOTEC | 6,698 | -0,86 % | Adidas, Bechtle, Bitcoin Group, Evotec, Renk, Ströer - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| BIONTECH | 87,95 | -2,66 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,305 | -10,16 % | Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference | ||
| BEAM THERAPEUTICS | 26,340 | -5,49 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
| APOGEE THERAPEUTICS | 52,45 | -1,43 % | Apogee Therapeutics sichert sich 323,3 Mio. US-Dollar durch Aktienplatzierung an der NASDAQ | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 10,290 | +9,35 % | Oppenheimer senkt Kursziel für Moonlake Immunotherapeutics nach durchwachsenen Studienergebnissen | ||
| MINERALYS THERAPEUTICS | 42,170 | +6,95 % | Mineralys Therapeutics: Aktie erreicht Rekordhoch von 41,11 USD | ||
| VIKING THERAPEUTICS | 28,860 | -4,64 % | Why Shares in Viking Therapeutics Surged This Week | ||
| ARCELLX | 86,80 | -1,84 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| COGENT BIOSCIENCES | 16,250 | +0,37 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 20,740 | -5,86 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| JYONG BIOTECH | 54,99 | +2,84 % | Jyong Biotech Ltd.: Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS-8 for Prostate Cancer Prevention | New Taipei City, Taiwan, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company", "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,320 | -5,87 % | UBS bestätigt Kaufempfehlung für Summit Therapeutics vor ESMO-Daten | ||
| AVIDITY BIOSCIENCES | 49,740 | -1,99 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen |
ASCENTAGE PHARMA GROUP INTERNATIONAL ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -1,600 (-4,85 %) liegt der Kurs bei 31,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCENTAGE PHARMA GROUP INTERNATIONAL ADR finden Sie auf Wallstreet Online.